Ekins; Sean

Patent Applications and Registrations

Patent applications and USPTO patent grants for Ekins; Sean.The latest application filed is for "isoxazole-3-carboxamide derivatives and their use for treatment of diseases caused by virus infection".

Company Profile

3.5.15

Ekins; Sean - Fuquay Varina NC
Ekins; Sean - Raleigh NC
EKINS; Sean - New Brunswick NJ
Ekins; Sean - Jenkintown PA
Ekins; Sean - Indianapolis IN

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Isoxazole-3-carboxamide Derivatives And Their Use For Treatment Of Diseases Caused By Virus Infection App 20220298149 - Makarov; Vadim ; et al.	2022-09-22
Methods and compositions for modulating .beta.-amyloid/.alpha.7-nAChR interactions Grant 11,382,875 - McMurtray , et al. July 12, 2	2022-07-12
Therapeutic Indazoles App 20220144781 - FREUNDLICH; Joel S. ; et al.	2022-05-12
Therapeutic indazoles Grant 11,186,549 - Freundlich , et al. November 30, 2	2021-11-30
Enzyme Replacement Therapy For Mucopolysaccharidosis Iiid App 20210015906 - Dickson; Patricia ; et al.	2021-01-21
Inhibitors of bacterial growth Grant 10,695,322 - Lamichhane , et al.	2020-06-30
Therapeutic Indazoles App 20200199076 - FREUNDLICH; Joel S. ; et al.	2020-06-25
Novel Inhibitors Of Bacterial Growth App 20190167637 - Lamichhane; Gyanu ; et al.	2019-06-06
Enzyme Replacement Therapy For Mucopolysaccharidosis Iiid App 20180221459 - Dickson; Patricia ; et al.	2018-08-09
Glutamate receptor modulators and therapeutic agents Grant 8,211,882 - Wood , et al. July 3, 2	2012-07-03
System And Method For Prediction Of Drug Metabolism, Toxicity, Mode Of Action, And Side Effects Of Novel Small Molecule Compounds App 20120029896 - Ekins; Sean ; et al.	2012-02-02
System And Method For Prediction Of Drug Metabolism, Toxicity, Mode Of Action, And Side Effects Of Novel Small Molecule Compounds App 20100250218 - EKINS; Sean ; et al.	2010-09-30
Glutamate receptor modulators and therapeutic agents App 20090239919 - Wood; Richard Delarey ; et al.	2009-09-24
System and method for prediction of drug metabolism, toxicity, mode of action, and side effects of novel small molecule compounds App 20070219768 - Ekins; Sean ; et al.	2007-09-20
Pharmacophore models for, methods of screening for, and identification of the cytochrome P-450 inhibitory potency of neurokinin-1 receptor antagonists Grant 6,564,152 - Ekins , et al. May 13, 2	2003-05-13
Device for drug-drug interaction testing sample preparation App 20030069699 - Ekins, Sean ; et al.	2003-04-10
Pharmacophore models for, methods of screening for, and identification of the cytochrome P-450 inhibitory potency of neurokinin-1 receptor antagonists App 20020052693 - Ekins, Sean ; et al.	2002-05-02
Single point interaction screen to predict IC50 App 20020016681 - Ekins, Sean ; et al.	2002-02-07
Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors App 20020013372 - Ekins, Sean	2002-01-31
Method and device for drug-drug interaction testing sample preparation App 20010049092 - Ekins, Sean ; et al.	2001-12-06

Company Registrations

SEC

0001833454

Ekins Sean

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.